首页> 美国卫生研究院文献>Oncology Letters >Expression and clinical significance of SATB1 and TLR4 in breast cancer
【2h】

Expression and clinical significance of SATB1 and TLR4 in breast cancer

机译:SATB1和TLR4在乳腺癌中的表达及其临床意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This study investigated the expression of special AT-rich sequence-binding protein 1 (SATB1) and toll-like receptor 4 (TLR4) protein in breast cancer and its clinical significance. We collected breast cancer tissues from 120 patients and adjacent non-cancerous tissue from 53 patients. SATB1 was expressed in 89 cases of breast cancer (74.17%) and in 7 cases of adjacent non-cancerous tissue (13.21%). TLR4 was expressed in 70 cases of breast cancer tissues (58.33%) and in 48 cases of adjacent non-cancerous tissue (90.57%). The differences of SATB and TLR4 in breast cancer and adjacent non-cancerous tissue were statistically significant. We found a negative correlation between the expression of SATB1 and TLR4 (r=−0.624, P<0.05). The expression of SATB1 and TLR4 were not significantly correlated with age, menopause, and PR and HER-2 protein expression, but were significantly correlated with tumor size, local lymphatic metastasis, histopathological grade, tumor stage, and ER protein expression (P<0.05). Overall, SATB1 and TLR4 proteins are involved in the development of breast cancer, a finding of great significance to identify therapeutic targets and prognosis markers for breast cancer.
机译:本研究探讨了富含AT的特殊序列结合蛋白1(SATB1)和Toll样受体4(TLR4)蛋白在乳腺癌中的表达及其临床意义。我们收集了120例患者的乳腺癌组织和53例患者的邻近非癌组织。 SATB1在89例乳腺癌(74.17%)和7例邻近非癌组织中表达(13.21%)。 TLR4在70例乳腺癌组织(58.33%)和48例相邻的非癌组织(90.57%)中表达。乳腺癌和邻近非癌组织中SATB和TLR4的差异具有统计学意义。我们发现SATB1和TLR4的表达呈负相关(r = -0.624,P <0.05)。 SATB1和TLR4的表达与年龄,更年期,PR和HER-2蛋白表达无显着相关性,但与肿瘤大小,局部淋巴转移,组织病理学分级,肿瘤分期和ER蛋白表达显着相关(P <0.05 )。总体而言,SATB1和TLR4蛋白与乳腺癌的发展有关,这一发现对于确定乳腺癌的治疗靶点和预后标志物具有重要意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号